Ossur hf
OTC:OSSUY
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IS |
O
|
Ossur hf
CSE:OSSR
|
11.3B DKK |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
188.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
168.4B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
130B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
112B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
102.5B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.9B EUR |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.6B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
45.8B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.5B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
33.7B USD |
Loading...
|
Market Distribution
| Min | 0.1% |
| 30th Percentile | 0.4% |
| Median | 9.5% |
| 70th Percentile | 41% |
| Max | 86.6% |
Other Profitability Ratios
Ossur hf
Glance View
Össur hf. is an Icelandic company that stands as a quiet marvel in the realm of orthopedic innovation, specializing in the development of non-invasive equipment designed to enhance human mobility. Born out of a small prosthetics shop in Reykjavik in 1971, the company has grown into a global leader in orthopedic solutions. At its core, Össur's operations revolve around the invention and commercialization of cutting-edge prosthetics, braces, and supports aimed at improving the quality of life for people who face limb challenges due to injuries, disabilities, or age-related conditions. The company's ethos of "Life Without Limitations" guides its pursuit to blend medical technology and engineering in a way that restores human dignity and functionality, manifesting a unique synergy between advanced robotics and biology. Commercially, Össur thrives by leveraging its commitment to research and development, channeling substantial investment into creating high-demand products characterized by reliability, adaptability, and innovation. Revenue streams primarily flow from the sale of prosthetic limbs and associated components, together with orthopedic support products that are distributed both directly and through a network of wholesalers and medical professionals worldwide. By maintaining a diversified product line and focusing on customer-centric customization, Össur meets a significant demand within healthcare systems, insurance providers, and direct consumer markets. The company's ability to translate its scientific prowess into marketable and life-enhancing solutions has cemented its reputation as a key player in the med-tech industry, aligning financial success with a meaningful social mission.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Ossur hf is 61.4%, which is below its 3-year median of 61.6%.
Over the last 3 years, Ossur hf’s Gross Margin has decreased from 62.5% to 61.4%. During this period, it reached a low of 61.2% on Dec 31, 2022 and a high of 63.6% on Jun 30, 2021.